10 Reasons Cybersecurity Vendors Fail MedTech

Free Buyer’s Guide · 10 Pages · Updated Apr 2026

A practical, ungated buyer’s guide for manufacturers comparing Blue Goat Cyber to platform vendors, hospital network defense firms, and generalist consultancies. What goes wrong, why it costs you, and what to demand from your next partner.

• 250+ - Devices Cleared
• 0 - FDA Rejections
• 24h - Fixed-Fee Quote
• 100% - Clearance Guarantee (Context)

Why this guide exists

Choosing a medical device cybersecurity partner is one of the highest-leverage regulatory decisions your team will make. Get it right and your submission clears on the first cycle. Get it wrong and you pay twice - once for the original work, and again for the rework after FDA’s Additional Information (AI) letter.

Section 524B of the FD&C Act gives FDA explicit authority to refuse any premarket submission for a cyber device that doesn’t meet cybersecurity requirements. The agency’s February 2026 guidance, anchored in the new QMSR (21 CFR Part 820), which incorporates ISO 13485:2016 by reference, has sharpened expectations around interoperability, TPLC security risk management, and unresolved anomalies.

After 250+ premarket submissions with zero rejections, we see the same vendor failure modes play out again and again. This guide names them, explains the cost, and tells you what to demand from the partner you choose next - whether or not that partner is us.

How to use this guide

• Read each reason as a vendor scorecard - does your current or prospective partner avoid this trap?
• Use the 10-point scorecard at the end to score finalists side-by-side before signing.
• Where you find a gap, the timeline reality check tells you what good looks like.

Where partners go wrong - and what it costs you

Each failure mode below is drawn from real submission cycles. Use this as your evaluation checklist.

They sell you a software platform when you need a submission

What you typically see

Platform vendors will license you an SBOM, vulnerability management, or runtime security platform. The dashboard looks great. But FDA does not accept dashboards - they accept submission artifacts.

Why it costs you

You still need someone to produce the threat model, Security Risk Assessment (per AAMI SW96), pen test report, SPDF documentation, and labeling. The seat license is a recurring cost on top of the consulting work you didn’t avoid.

What we do differently

• We deliver the FDA-ready package itself: threat modeling, SBOM, Security Risk Assessment (per AAMI SW96), pen test, SPDF, labeling - formatted to the Feb 2026 guidance.
• Fixed-fee engagement aligned to your submission. No seat licenses. No dashboards to maintain.
• If you already own a tool, we use it. If you don’t, we don’t make you buy one.

They sell hospital network defense, not pre-market clearance

What you typically see

Hospital network defense vendors monitor devices already deployed inside hospitals. Useful for the IDN buyer. Useless for the manufacturer trying to clear a device.

Why it costs you

Pre-market submission requires evidence built into the device design, not telemetry from the field. Engaging a hospital-network vendor for 510(k) work delays the submission and produces the wrong artifacts.

What we do differently

• We work exclusively with manufacturers building devices, not hospitals operating them.
• Every deliverable maps directly to FDA premarket cybersecurity guidance and the QMSR (21 CFR Part 820).
• We’ve supported 510(k), De Novo, and PMA across imaging, surgical robotics, diagnostics, wearables, and connected hospital systems. Explore our services.

Generalist consultancies that learn medical devices on your dime

What you typically see

Large IT-security firms and big-four advisory practices stretch generalist talent across many verticals. The named partner pitches the work; juniors execute it.

Why it costs you

AAMI TIR57, IEC 81001-5-1, ISO 14971 hazard linkage, and the FDA’s expectations around interoperability and TPLC require people who do this every day. Generalists trigger AI letters because they miss the medical-device context.

What we do differently

• Our team is OSCP, CISSP, GPEN credentialed and works exclusively in medical-device cybersecurity. Meet the team.
• Senior practitioners do the work - not a partner pitch followed by a junior delivery team.
• We’ve cleared 250+ devices across 510(k), De Novo, and PMA pathways with zero rejections.

Comparing vendors right now?

We’ll review your shortlist on a free 30-minute call.

Talk to an expert

Hourly billing with no ceiling and no clear scope

What you typically see

Discovery call. SOW with a budget range. Then weekly invoices that drift past the original estimate - especially after the first FDA round of feedback.

Why it costs you

Cybersecurity is the line item your CFO can’t predict. Open-ended billing kills internal champions and stalls submissions while you renegotiate scope.

What we do differently

• Fixed-fee quote within 24 hours of your discovery session.
• Scope and deliverables defined up front, mapped to your submission pathway.
• Unlimited retests until you clear. We absorb the risk, not your budget.

4 to 8 week onboarding queues you can’t afford

What you typically see

You sign in February. Kickoff in April. First deliverable in May. Meanwhile your submission window shifts and engineering loses momentum.

Why it costs you

Cyber is rarely the long pole - until a vendor makes it one. Once a queue puts you behind, every other workstream (regulatory, clinical, manufacturing) slips with it.

What we do differently

• We can kick off this week. Our agile delivery model and well-defined process don’t require a queue.
• If your FDA submission deadline is tight, we are built for it. Most engagements complete in 4 to 8 weeks.
• Discovery call to scoped quote in 24 hours so you can lock the timeline immediately.

Pen tests that miss the device and check a box

What you typically see

Web-app scan. Network sweep. A scanner report rebadged with a logo. No analysis of BLE pairing, USB attack surface, OTA update path, or the cloud back end the device talks to.

Why it costs you

FDA’s Feb 2026 guidance expects testing that exercises every interface, by testers who understand the device. A generic external pen test does not satisfy that bar and almost guarantees a deficiency.

What we do differently

• Manual testing across every interface: wireless, USB, BLE, cellular, cloud APIs, and service ports.
• Testers receive your threat model, SBOM, and architecture views before they touch the device.
• Findings tied directly to the threat model and risk file so reviewers see the loop closed.

No FDA clearance guarantee - only a best effort

What you typically see

The proposal says “we will support you through any FDA feedback at our standard rate.” Translation: if FDA pushes back, you pay again to fix what should have been right.

Why it costs you

A vendor that won’t stand behind their work has nothing at stake. You carry 100% of the rejection risk while they collect 100% of the original fee.

What we do differently

• 100% FDA cybersecurity clearance guarantee. If your submission is rejected for cyber reasons we covered, we fix it free.
• We do this because we know the work. 250+ devices cleared, zero rejections.
• Skin in the game means we will not let an under-scoped deliverable leave the building.

Deliverables that don’t drop into your QMS

What you typically see

Beautiful PDFs that don’t reference your design controls, ISO 13485 clauses, or the QMSR (21 CFR Part 820) processes your team actually runs. Your eQMS team rewrites everything before it lands in the DHF.

Why it costs you

Rework is expensive, and an inconsistent paper trail between cyber and design controls is itself a deficiency. Reviewers spot mismatched language and dates immediately.

What we do differently

• Every deliverable is mapped to your design controls and ISO 13485 clauses (e.g., 7.3 Design and Development).
• We integrate with your existing eQMS and risk management processes so artifacts drop into your DHF without rework.
• Cybersecurity risks are tied to ISO 14971 hazards, not maintained in a separate file.

Pre-market only - no post-market or TPLC plan

What you typically see

Vendor disappears the day you submit. Then FDA’s TPLC Security Risk Management section, your CVD program, and post-market surveillance reporting all become your team’s problem.

Why it costs you

Section 524B and the Feb 2026 guidance treat post-market cyber as an explicit submission element. Without a credible monitoring and patch plan, your premarket controls don’t stand on their own.

What we do differently

• We operationalize SBOM monitoring, coordinated vulnerability disclosure (CVD), patch management, and post-market surveillance.
• Available as a one-time program build or an ongoing managed service - your choice.
• Aligned to ISO/IEC 29147 and 30111, FDA’s Refuse-to-Accept policy, and your QMSR-aligned servicing process.

US-only thinking when you need EU MDR and beyond

What you typically see

Documentation written for FDA only. EU Notified Body, MHRA, Health Canada, and TGA reviewers receive the same package and ask for mappings the vendor never produced.

Why it costs you

Connected devices ship globally. Re-doing security documentation per jurisdiction wastes months. International reviewers are increasingly aligned to IEC 81001-5-1 and EU MDR Annex I cybersecurity expectations.

What we do differently

• One package mapped to FDA, IEC 81001-5-1, IEC 62304, AAMI TIR57, ISO 14971, and EU MDR Annex I cybersecurity requirements.
• Submissions supported across FDA, Health Canada, MHRA, TGA, and EU Notified Bodies.
• Future-proofed for evolving global cybersecurity requirements without rewriting your DHF.

Second set of eyes?

Want a review of your cyber package before you submit? We do a fixed-fee gap analysis in days.

Talk to an expert

Vendor Scorecard

Score each finalist against these ten criteria. A vendor that can’t honestly check all ten will cost you time, money, or a clearance.

Timeline Reality Check

Vendor proposals routinely understate cyber effort. Here is what a complete cyber package typically takes for a moderate-complexity Class II connected device - when the work is done right the first time and the team can actually start this week:

WorkstreamTypical Effort

Discovery, scoping, fixed-fee quote24 hours

Security Risk Assessment integrated with ISO 149712 to 3 weeks

Cybersecurity labeling + CVD program1 to 2 weeks

Note: Some artifacts run in parallel. Most teams need 8 to 12 weeks of focused work; rework after an AI letter typically adds 8 to 12 additional weeks to clearance.